{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:21:45Z","timestamp":1792516905350,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,29]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Serous endometrial intraepithelial carcinoma (SEIC) is a rare, non-invasive lesion of the endometrial epithelium, typically characterised by p53 abnormalities. Although regarded as a precursor lesion, recent classification systems increasingly position SEIC within the broader spectrum of serous carcinomas and current guidelines place non-invasive p53-abnormal serous lesions in an uncertain risk category due to limited outcome data. As a result, SEIC is not consistently addressed as a distinct diagnosis, contributing to variation in clinical management. Complete surgical staging, including pelvic and para-aortic lymph node assessment, is frequently performed, yet supporting evidence remains scarce. This study aims to collect longitudinal data to evaluate surgical management strategies in relation to clinical outcomes, survival and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre prospective observational cohort will enrol patients diagnosed with SEIC or equivalent non-invasive serous lesions who provide informed consent. Data will be collected using electronic case report forms (Castor Electronic Data Capture). Baseline clinical, pathological, molecular and treatment data will be collected, including imaging, histopathology, immunohistochemistry and molecular classification when available. Patient-reported outcomes will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Endometrial Cancer Module (EORTC QLQ-EN24) and EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) questionnaires at baseline, 6\u2009months, 2 years and 5 years after diagnosis. The primary outcome is progression-free survival, secondary outcomes include overall survival, health-related quality of life and adverse events. Analyses will be primarily descriptive. Survival outcomes will be estimated using Kaplan-Meier methods, with Cox proportional hazards modelling used to explore predictors of outcome where feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study will be conducted in accordance with the Declaration of Helsinki and applicable regulations. Ethical approval was obtained at the Erasmus MC (MEC-2025-0368). Results will be disseminated through peer-reviewed publications and scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06677242\">NCT06677242<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-120737","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:40:27Z","timestamp":1786110027000},"page":"e120737","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Intraepithelial serous carcinoma of the endometrium: protocol for a prospective multicentre registry in the Netherlands"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06677242","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-7522","authenticated-orcid":false,"given":"F Ciska","family":"Slaager","sequence":"first","affiliation":[{"name":"Gynaecological Oncology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas J","family":"Hoogduin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pathan BV, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward","family":"Hofhuis","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-561X","authenticated-orcid":false,"given":"Floris H","family":"Groenendijk","sequence":"additional","affiliation":[{"name":"Pathology, Erasmus MC Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-7412","authenticated-orcid":false,"given":"Heleen J","family":"van Beekhuizen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Erasmus MC Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026080706402202000_16.8.e120737.1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CMAR.S45141","article-title":"Serous endometrial intraepithelial carcinoma: a case series and literature review","volume":"5","author":"Pathiraja","year":"2013","journal-title":"Cancer Manag Res"},{"key":"2026080706402202000_16.8.e120737.2","unstructured":"Organization WH . Female genital tumours: WHO classification of tumours."},{"key":"2026080706402202000_16.8.e120737.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30496"},{"key":"2026080706402202000_16.8.e120737.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs345"},{"key":"2026080706402202000_16.8.e120737.5","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-200107000-00002"},{"key":"2026080706402202000_16.8.e120737.6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3802\/jgo.2011.22.1.53","article-title":"A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination","volume":"22","author":"Kawano","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"2026080706402202000_16.8.e120737.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-016-0585-0","article-title":"Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions","volume":"11","author":"Furuya","year":"2016","journal-title":"Diagn Pathol"},{"key":"2026080706402202000_16.8.e120737.8","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e3181b1d10e"},{"key":"2026080706402202000_16.8.e120737.9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800271"},{"key":"2026080706402202000_16.8.e120737.10","doi-asserted-by":"crossref","DOI":"10.1038\/nature12325","article-title":"Erratum: Integrated genomic characterization of endometrial carcinoma","volume":"500","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2026080706402202000_16.8.e120737.11","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200006000-00004"},{"key":"2026080706402202000_16.8.e120737.12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11864-025-01314-8","article-title":"Therapeutic Challenges in the Management of Serous Endometrial Intraepithelial Carcinoma (SEIC)","volume":"26","author":"Hicks","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"2026080706402202000_16.8.e120737.13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejogrb.2021.08.012","article-title":"Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands","volume":"265","author":"Slaager","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026080706402202000_16.8.e120737.14","unstructured":"WHO Classification of Tumours Editorial Board . WHO classification of tumours, female genital tumours. Lyon International Agency for Research on Cancer."},{"key":"2026080706402202000_16.8.e120737.15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00167-6"},{"key":"2026080706402202000_16.8.e120737.16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0006"},{"key":"2026080706402202000_16.8.e120737.17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae Insights: Uterine Neoplasms, Version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026080706402202000_16.8.e120737.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3248"},{"key":"2026080706402202000_16.8.e120737.19","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.7314\/APJCP.2015.16.13.5483","article-title":"Comparison of Perioperative and Oncologic Outcomes with Laparotomy, and Laparoscopic or Robotic Surgery for Women with Endometrial Cancer","volume":"16","author":"Manchana","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026080706402202000_16.8.e120737.20","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004281"},{"key":"2026080706402202000_16.8.e120737.21","unstructured":"ValidSign: secure digital signature and e-signing platform. Eefde, The Netherlands ValidSign; 2026. Available: https:\/\/www.validsign.eu"},{"key":"2026080706402202000_16.8.e120737.22","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2026080706402202000_16.8.e120737.23","unstructured":"Institute NC . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD: U.S. Department of Health and Human Services, 2017."},{"key":"2026080706402202000_16.8.e120737.24","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:40:29Z","timestamp":1786110029000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-120737"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120737","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}